Clinical trials: Respiratory Allergy
Asthma
International Cross-sectional and Longitudinal Assessment on Asthma Control (Liaison)
The study design consists of a cross-sectional survey on the clinical characteristics of patients with asthma and their level of asthma control and current quality of life, and on a prospective evaluation of the rate of switch…
- Trial name
- LIAISON (NCT01567280)
- Where
- Italy
- Volunteers
- 8,111 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo
This purpose of the study is to investigate if budesonide pMDI 160 �g twice a day during 6 weeks is effective and safe in treating asthmatic children aged 6 to <12 years
- Trial name
- CHASE 1 (NCT01136382)
- Testing
- budesonide
- Where
- 87 sites in United States, Bulgaria and 5 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Asthma
Integrated Digitally Enhanced Care for Long-term Conditions- Asthma
Asthma is a common lung condition that causes long term breathing difficulties. There is currently no cure for asthma but the use of simple inhaler treatments can keep the symptoms under control.
- Trial name
- IDEAL (NCT03511482)
- Testing
- myAsthma Application, Lloyds Pharmacy Online Doctor
- Where
- United Kingdom
- Sponsor
- my mhealth Ltd
Asthma
Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from…
- Trial name
- NCT01128595
- Testing
- FF/GW642444M, GW642444M, Fluticasone Furoate
- Where
- 4 sites in Australia, New Zealand and 1 more
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Asthma, Allergic Rhinitis
A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)
Subjects have 8-week with montelukast sodium or comparator drug administration period, 2-week wash-out period and 8-week comparator drug or the drug administration period (with cross-over design) for assessment of the drug…
- Trial name
- NCT00157937
- Testing
- MK0476; montelukast sodium/Duration of Treatment: 16 weeks, Comparator: theophylline ER/Duration of Treatment: 16 weeks
- Volunteers
- 31 people
- Sponsor
- Organon and Co
Asthma
A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528
To evaluate the effect of MEDI-528 in adults with atopic asthma.
- Trial name
- NCT00483041
- Testing
- MEDI528 9 mg/kg
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- MedImmune LLC
Allergic Rhinitis
Study of CM310 in Patients With Allergic Rhinitis
This study is a multicenter, single arm, open-label phase II clinical study mainly evaluating the safety of CM310 in patients with allergic rhinitis.
- Trial name
- NCT05908721
- Testing
- CM310
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Keymed Biosciences Co.Ltd
Asthma
Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients
The objective of this study is to assess the efficacy and safety of SOTB07 in asthma patients by observing changes FEV1 (% predicted) as the primary efficacy endpoint after oral administration of SOTB07 200mg, 400mg, placebo for…
- Trial name
- NCT01907763
- Testing
- SOTB07 200mg, SOTB07 400mg
- Where
- South Korea
- Volunteers
- 194 people
- Sponsor
- SK Chemicals Co., Ltd.
Asthma
Asthma Control Among Patients Receiving Inhaled Corticosteroids in Thailand
The purpose of this study is to determine the percentage of patients who has reached the GINA guideline of asthma treatment after receiving any inhaled corticosteroid for 3 months or longer in actual clinical practice.
- Trial name
- NCT00800904
- Where
- 26 sites in Thailand
- Volunteers
- 1,210 people
- Sponsor
- AstraZeneca
Asthma
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma.
- Trial name
- NCT00467740
- Testing
- BI 1744 CL
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study of MRx-4DP0004 in Asthma
This is a multicentre, phase I/II, double-blind, placebo-controlled study of MRx-4DP0004 in participants taking long-term medication for asthma.
- Trial name
- NCT03851250
- Testing
- MRx-4DP0004
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 34 people
- Sponsor
- 4D pharma plc
Allergic Rhinitis
Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis
This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis
- Trial name
- NCT00929968
- Testing
- VAK694, Fluticasone
- Where
- 2 sites in United States, Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Persistent Asthma
Study of Safety of Foradil in Patients With Persistent Asthma
The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and…
- Trial name
- NCT01845025
- Testing
- Formoterol 12 mcg, Fluticasone propionate 100 mcg, Fluticasone propionate 250 mcg
- Where
- 27 sites in United States
- Volunteers
- 827 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Investigation Of A New Medication (GW642444) In Asthmatic Patients
This study will evaluate efficacy (FEV1), safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat inhaled doses of GW642444.
- Trial name
- NCT00354874
- Testing
- GW642444, salmeterol 50mcg
- Where
- 3 sites in Germany, Sweden
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma
A Trial of SHR-1703 in Healthy Adults
SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the first study in Healthy subjects. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of…
- Trial name
- NCT04480762
- Testing
- SHR-1703
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Asthma
FASENRA SCEI for Long-term Use
The purpose of the investigation is to confirm the safety and efficacy under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe.
- Trial name
- NCT03588546
- Where
- 29 sites in Japan
- Volunteers
- 653 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic
Glycyphagus Domesticus Allergen Extract. Determination of the in Vivo Biological Activity in Histamine Equivalent Units (HEP).
The main purpose of the trial is to prove the therapeutic value of the product and enable an effective and safe dosage schedule to be recommended
- Trial name
- NCT00917488
- Testing
- Standardization of allergenic extract (Gly. domesticus)
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- Laboratorios Leti, S.L.
Asthma
Efficacy of LAMA Added to ICS in Treatment of Asthma (ELITRA)
Primary objective The primary objective was to evaluate the superiority of CHF 5259 (glycopyrronium bromide [GB]) in a pressurised metered dose inhaler (pMDI) (50 μg total daily dose) versus placebo in terms of forced expiratory…
- Trial name
- ELITRA (NCT02296411)
- Testing
- CHF 5259 12.5 µg + Qvar
- Where
- 28 sites in Bulgaria, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
TC-6987 for the Treatment of Mild to Moderate Asthma
This study is designed to determine whether TC-6987 improves respiratory function in subjects with asthma by reducing airway hyper-responsiveness and inflammation.
- Trial name
- NCT01296087
- Testing
- TC-6987
- Where
- 21 sites in United States
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Asthma
BI 443651 Methacholine Challenge
The primary objective of this study is to investigate safety and tolerability of three consecutive administrations, 12 hours apart, at three different dose-levels of BI 443651 administered via oral inhalation in male and female…
- Trial name
- NCT03135899
- Testing
- BI 443651
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.